Another delay it is. Fokking Culley is already negotiating with Hercules Capital.
Culley lost all credibility already. So nothing can be demolished in this respect.
Bla bla bla
Here is what Culley will say: ladies and gentlemen, I tricked you again with a further data delay and an additional round of financing. You fokking stockholders just don't deserve better.
Keryx Biopharmaceuticals, with headquarters in Boston, is focused on bringing innovative medicines to people with renal disease. In December 2014, the company launched its first FDA-approved medicine, Auryxia® (ferric citrate) in the United States. In January 2014, ferric citrate was approved for use in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex).
That summary deserves a big fat LOL!
The only hope I have that Seth realizes now this is an inept management and forces a fire sale. Recovery is impossible.
What's missing on your list is what the company eventually may kill.
After three months with the drug off the market they can relaunch the drug. That's a really tough task for a company which couldn't do it right the first time. Now, this time they have to launch it against the believe they can't really produce it reliably. They better look for a suitor sooner rather than later. Price doesn't matter anymore. Just hope you get a little premium.
I think we talked about this. How can tax rate for long or short capital gains impact SK's decision to sell? Did he already convert his entire loan after the annual meeting?
Your pt of $2 is way too aggressive. That would have been possible with top line data in Q1 as originally promised. Now everybody knows the company cannot flawless execute. The post result era will be a mirrow image what we have been through the last 18 months. We can be happy if it reaches $1 after data for a short period of time. So I will be extremely happy to double my money but this is even doubtful if there is a 5th, 6th etc amendment. Sorry but $2 is delusional. Also there will be a heavy dilution again after data release. My guess is 50 to 100 million shares. That threat already prevents a strong price appreciation.
As we also know there is no business development activity where we could hope for a cash rich partner. This baby will go down the drain over the next few years. Management is completely inexperienced just hot to get the paycheck.